Arrhythmogenic Ventricular Remodeling by Next-Generation Bruton’s Tyrosine Kinase Inhibitor Acalabrutinib
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25116207 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Yanan Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2M1, Canada. Hauptthemen laut MEDLINE: Benzamides, Rats, Sprague-Dawley, Agammaglobulinaemia Tyrosine Kinase, Arrhythmias, Cardiac. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research (CIHR).
Abstract (Originalsprache)
Cardiac arrhythmias remain a significant concern with Ibrutinib (IBR), a first-generation Bruton’s tyrosine kinase inhibitor (BTKi). Acalabrutinib (ABR), a next-generation BTKi, is associated with reduced atrial arrhythmia events. However, the role of ABR in ventricular arrhythmia (VA) has not been adequately evaluated. Our study aimed to investigate VA vulnerability and ventricular electrophysiology following chronic ABR therapy in male Sprague–Dawley rats utilizing epicardial optical mapping for ventricular voltage and Ca2+ dynamics and VA induction by electrical stimulation in ex-vivo perfused hearts. Ventricular tissues were snap-frozen for protein analysis for sarcoplasmic Ca2+ and metabolic regulatory proteins. The results show that both ABR and IBR treatments increased VA vulnerability, with ABR showing higher VA regularity index (RI). IBR, but not ABR, is associated with the abbreviation of action potential duration (APD) and APD alternans. Both IBR and ABR increased diastolic Ca2+ leak and Ca2+ alternans, reduced conduction velocity (CV), and increased CV dispersion. Decreased SERCA2a expression and AMPK phosphorylation were observed with both treatments. Our results suggest that ABR treatment also increases the risk of VA by inducing proarrhythmic changes in Ca2+ signaling and membrane electrophysiology, as seen with IBR. However, the different impacts of these two BTKi on ventricular electrophysiology may contribute to differences in VA vulnerability and distinct VA characteristics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2M1, Canada.
- Ted Rogers Centre for Heart Research, Toronto, ON M5G 1M1, Canada.
- Women's College Hospital, Toronto, ON M5S 1B2, Canada.
ORCID-Profile: Yanan Zhao, Stéphane Massé, Filio Billia, Patrick F H Lai
Förderung
- CIHR
- Canadian Institutes of Health Research (CIHR)
Zitieren
APA
Zhao, Y., Chakraborty, P., Tomassetti, J., Subha, T., Massé, S., Thavendiranathan, P., Billia, F., Lai, P. F. H., Abdel-Qadir, H., & Nanthakumar, K. (2024). Arrhythmogenic Ventricular Remodeling by Next-Generation Bruton’s Tyrosine Kinase Inhibitor Acalabrutinib. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25116207
Vancouver
Zhao Y, Chakraborty P, Tomassetti J, Subha T, Massé S, Thavendiranathan P, et al. Arrhythmogenic Ventricular Remodeling by Next-Generation Bruton’s Tyrosine Kinase Inhibitor Acalabrutinib. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25116207
BibTeX
@article{Zhao2024,
author = {Zhao, Yanan and Chakraborty, Praloy and Tomassetti, Julianna and Subha, Tasnia and Massé, Stéphane and Thavendiranathan, Paaladinesh and Billia, Filio and Lai, Patrick F H and Abdel-Qadir, Husam and Nanthakumar, Kumaraswamy},
title = {Arrhythmogenic Ventricular Remodeling by Next-Generation Bruton’s Tyrosine Kinase Inhibitor Acalabrutinib},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25116207}
}
EUVIMED